ADMA Biologics

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ADMA Biologics reports robust Q4 results and outlines growth strategies

ADMA Biologics demonstrated strong financial performance and strategic progress in Q4 2022, positioning the company for growth.
The company's focus on operational excellence, product performance, and market acceptance underpins its growth strategy.
Challenges in achieving profitability and market expansion are being addressed through strategic initiatives and operational enhancements.
Opportunities in label expansions, plasma donor targeting, and manufacturing scale-up offer avenues for sustained growth and market differentiation.

ADMA Biologics reports record revenue growth and profitability in Q1

ADMA Biologics demonstrated strong financial performance in Q1 2023, with notable revenue growth and achieving adjusted EBITDA profitability for the first time.
While facing regulatory and operational challenges, the company is strategically positioned for growth, focusing on immune globulin products and patient outcomes.
Management's commitment to innovation, cost efficiencies, and market expansion underscores ADMA's dedication to driving revenue growth and achieving profitability.

ADMA Biologics reports robust Q2 earnings and growth outlook

ADMA Biologics delivered strong financial results, raised revenue guidance, and showcased operational efficiency, positioning the company for sustained growth and market leadership.
The success of ASCENIV and the company's focus on plasma collection underscore ADMA's commitment to patient care, innovation, and social responsibility in the biologics sector.
While facing challenges in a competitive landscape, ADMA has opportunities to expand market reach, increase awareness, and solidify its position as a unique player in the industry.
By balancing financial objectives with social impact goals and emphasizing market differentiation, ADMA can navigate challenges and leverage opportunities for long-term success and stakeholder value.

ADMA Biologics achieves profitability in Q3, poised for growth

ADMA Biologics delivered a strong performance in Q3 2023, achieving profitability for the first time and demonstrating robust revenue growth.
The company's focus on ASCENIV, gross margin improvement, and revenue guidance raise optimism for future prospects and market positioning.
While facing challenges in debt refinancing and patient activation, ADMA Biologics is well-positioned to capitalize on opportunities in product enhancement and market expansion.
Overall, ADMA Biologics' strategic initiatives and financial performance in Q3 indicate a positive trajectory for growth and profitability in the biologics market.

ADMA Biologics achieves positive earnings, focuses on innovation and growth

ADMA Biologics reported a strong financial performance in Q4 2023, achieving positive adjusted net income and cash flow. The company emphasized innovation, growth strategies, and operational efficiencies to drive future success.
While facing challenges in managing profitability and debt, ADMA Biologics is focused on maintaining a strong gross margin profile and developing products targeting specific infectious diseases. The company's commitment to shareholder returns and revenue growth presents opportunities for sustained success.
Overall, ADMA Biologics showcased resilience and strategic planning during the earnings call, with a clear focus on financial stability, innovation, and maximizing shareholder value. The company's positive outlook and growth initiatives position it well for future growth and market competitiveness.

ADMA Biologics reports robust Q1 earnings, eyes sustained growth

ADMA Biologics delivered strong financial performance in Q1 2024, showcasing revenue growth, profitability, and upwardly revised guidance for 2024 and 2025, underlining their growth potential.
The company's focus on innovation, efficiency, and niche markets, along with confidence in long-term growth initiatives, positions them well for sustained value creation and revenue growth beyond 2025.
While facing challenges in operational efficiency, market penetration, and post-2025 revenue growth, ADMA Biologics remains optimistic about growth opportunities and revenue expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Conference Call Scheduled for November 9, 2022, at 4:30 p.m. ET

ADMA Biologics to Report Third Quarter 2022 Financial Results on November 9, 2022

FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth

ADMA BioCenters Receives FDA Approval for its Seventh Plasma Collection Center, Located in Greensboro, NC

Arcos Dorados Hlds

Crescent Point Energy

VAALCO Energy

Itau Unibanco Holding S.A.

Kosmos Energy

NL Industries

Some stocks under $10 are cheap for a reason, but there are other stocks under $10 that are solid long-term investments. There are all sorts of equities from which to choose when building your portfolio.

7 A-Rated Stocks to Buy for Less Than $10

AbbVie

Geron

Prometheus Biosciences

SIGA Technologies

Voyager Therapeutics

Axsome Therapeutics

A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter.

7 Top-Rated Biotech Stocks to Buy for Q4

Endo International

Volcon

Which meme penny stocks are you buying right now? The post How to Invest in Meme Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Invest in Meme Penny Stocks in 2022

ADMA Biologics recently reported their Q2 earnings with impressive revenue growth and improved margins. The company is on clear a path toward profitability. The market seems to have identified the opportunity that ADMA offers and has supported the share after hitting its low in October of last year.

ADMA Biologics: Strong Growth Is Clearing The Path To Profitability

Investors were pleasantly surprised by the company's latest set of quarterly figures.

Why ADMA Biologics Stock Triumphed on Thursday

ADMA Biologics, Inc. (NASDAQ:ADMA ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and Chief Executive Officer Brian Lenz - EVP, Chief Financial Officer and General Manager, ADMA BioCenters Conference Call Participants Elliot Wilbur - Raymond James Kristen Kluska - Cantor Fitzgerald Operator Good afternoon, and welcome to the ADMA Biologics Second Quarter 2022 Financial Results and Corporate Update Conference Call on Wednesday, August 10, 2022. At this time, all participants are in a listen-only mode.

ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q2 2022 Results - Earnings Call Transcript

2Q2022 Total Revenues Were $33.9 Million, a 90% Y-o-Y Increase

ADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adma Biologics (ADMA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Conference Call Scheduled for August 10, 2022, at 4:30 p.m. ET Conference Call Scheduled for August 10, 2022, at 4:30 p.m. ET

ADMA Biologics to Report Second Quarter 2022 Financial Results on August 10, 2022

Express

Gerdau

Which penny stocks are you buying right now? The post Need to Knows for Trading Penny Stocks in July  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Need to Knows for Trading Penny Stocks in July

Ramsey, N.J. and Boca Raton, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the Company will be added to the Russell 2000® Index, effective as of market open on June 27, 2022, according to a preliminary list of additions posted by FTSE Russell on June 17, 2022.

ADMA Biologics Announces Addition to the Russell 2000® Index

ADMA reported a great quarter in all respects. Management gave great guidance for 2024-2025 which shows that ADMA is undervalued with an enterprise value of only $324M.

ADMA Biologics: A Path To Profits Looks Clear

ADMA Biologics, Inc. (NASDAQ:ADMA ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and Chief Executive Officer Brian Lenz - Executive Vice President, Chief Financial Officer and General Manager, ADMA BioCenters Conference Call Participants Elliot Wilbur - Raymond James Kristen Kluska - Cantor Fitzgerald Operator Good afternoon, and welcome to the ADMA Biologics First Quarter 2022 Financial Results and Corporate Update Conference Call on Wednesday, May 11, 2022. At this time, all participants are in a listen-only mode.

ADMA Biologics, Inc.'s (ADMA) CEO Adam Grossman on Q1 2022 Results - Earnings Call Transcript

First Quarter 2022 Total Revenues Were Approximately $29.1 Million, an 81% Increase Over First Quarter 2021

ADMA Biologics Announces First Quarter 2022 Financial Results and Provides Business Update

Conference Call Scheduled for May 11, 2022 at 4:30 p.m. ET Conference Call Scheduled for May 11, 2022 at 4:30 p.m. ET

ADMA Biologics to Report First Quarter 2022 Financial Results on May 11, 2022

Institutional ownership has grown in the past 6 months. An activist investor is watching ADMA intently.

ADMA: Pertinent Updates

Aditxt Inc

Clovis Oncology

Can these penny stocks continue to climb after a bearish trading day? The post Best Penny Stocks to Watch After the Stock Market Takes a Bear Turn appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Watch After the Stock Market Takes a Bear Turn

RAMSEY, N.J. and BOCA RATON, Fla., April 01, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced a poster presentation and exclusive Key Opinion Leader symposium by nationally recognized clinical experts on the management of respiratory viral infections (RVIs) and real-world experience with ADMA's ASCENIV, a U.S. Food and Drug Administration (FDA)-approved intravenous immunoglobulin (IVIG) product with a unique composition.

ADMA Announces Live Poster Presentation and Symposium on Real-World Experience with ASCENIV™ at CIS 2022

ADMA reported full-year 2021 numbers on March 24, which disclosed higher than expected revenue, a lower than expected net loss, and strong 2022 guidance.

ADMA Biologics' 2021 Numbers Showed Continued Strong Execution

Agrify

Creative Medical Technology Holdings

Are these penny stocks on your April watchlist? The post Top Must-Watch Penny Stocks For Your April List  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Must-Watch Penny Stocks For Your April List

ADMA Biologics Inc (NASDAQ: ADMA) closed a debt refinancing with Hayfin Capital Management of $150 million, and up to an additional $25 million tied to specific revenue targets during 2022. The first tranche of the newly issued loan from Hayfin was fully drawn and used to completely repay the.

ADMA Biologics' Q4 Top-Line Surpass Estimates, Concludes $175M Debt Refinancing

Approval of 36-month shelf life encompasses all ASCENIV & BIVIGAM vial sizes, production scales, as well as internal and external fill-finishing

ADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV™ & BIVIGAM® from 24 to 36 Months

Full Year 2021 Total Revenues of Approximately $81 Million, a 92% Increase Over Full Year 2020

ADMA Biologics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update, Including $175M Debt Refinance with Hayfin Capital Management

News for ADMA Biologics Stock (ADMA)